Recently, there have been many advances in the investigation of the controversial roles that nitric oxide (NO) plays in various human cancers. These opposing roles as protumorigenic and antitumorigenic have been reported in the literature in various preclinical models. In general, international conferences on NO have focused primarily on its role in noncancer disease manifestations. Therefore, it became apparent that a more focused workshop on the role of NO in cancer was warranted, and so a series of workshops were initiated. The first was held in Paris, France; the second, in Kyoto, Japan; the third, in Kingston, Ontario, Canada; and the fourth, in Sevilla, Spain.
